Cartesian Therapeutics (RNAC) Research & Development: 2015-2025
Historic Research & Development for Cartesian Therapeutics (RNAC) over the last 11 years, with Sep 2025 value amounting to $13.8 million.
- Cartesian Therapeutics' Research & Development rose 21.07% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.7 million, marking a year-over-year decrease of 1.80%. This contributed to the annual value of $45.1 million for FY2024, which is 36.70% down from last year.
- Cartesian Therapeutics' Research & Development amounted to $13.8 million in Q3 2025, which was down 7.18% from $14.9 million recorded in Q2 2025.
- In the past 5 years, Cartesian Therapeutics' Research & Development registered a high of $21.9 million during Q4 2023, and its lowest value of $9.7 million during Q1 2024.
- In the last 3 years, Cartesian Therapeutics' Research & Development had a median value of $13.8 million in 2025 and averaged $14.5 million.
- In the last 5 years, Cartesian Therapeutics' Research & Development tumbled by 48.26% in 2024 and then skyrocketed by 50.69% in 2025.
- Quarterly analysis of 5 years shows Cartesian Therapeutics' Research & Development stood at $20.3 million in 2021, then declined by 6.65% to $19.0 million in 2022, then increased by 15.21% to $21.9 million in 2023, then slumped by 48.26% to $11.3 million in 2024, then grew by 21.07% to $13.8 million in 2025.
- Its Research & Development stands at $13.8 million for Q3 2025, versus $14.9 million for Q2 2025 and $14.7 million for Q1 2025.